Olivier Rigal
Olivier Rigal is an expert in Oncology at Centre Henri Becquerel (France). As of September 2026, ScienceLeadR ranks Olivier Rigal in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Olivier Rigal has authored 106 publications, the most recent in 2026, and is an investigator in 14 clinical trials, 4 of them ongoing. SLR score: 493 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Geriatrics - Nuclear Medicine - Dermatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2012 - 2026
Number : 106
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Research Study Attrition and Participant-Informed Retention Strategies Among Cancer Survivors. PMID 42734916 — feedback, cancer survivors, breast neoplasms, smokers, communication, neoplasms, income, cohort studies, breast, research, retention, psychology | JAMA Netw Open | 2026 | 0 |
| ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors. PMID 41667883 — cancer survivors, longitudinal studies, breast neoplasms, focus groups, neoplasms, breast | Breast Cancer Res Treat | 2026 | 0 |
| Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial. PMID 40752909 — breast neoplasms, neoplasms, drug therapy, aged, drug-related side effects and adverse reactions, chemotherapy, adjuvant, breast, therapeutics, frailty, chemotherapy | Lancet Top journal | 2025 | 1 |
| Supportive care structures and fundings in French Comprehensive Cancer Centers: a national survey. PMID 40448716 — neoplasms, therapeutics, palliative care | Support Care Cancer | 2025 | 0 |
| Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study. PMID 39972319 — apolipoprotein e4, cancer survivors, longitudinal studies, breast neoplasms, neoplasms, cognitive dysfunction, drug therapy, breast, cognition disorders, genotype, diagnosis, therapeutics, apolipoproteins e, memory, memory, episodic, chemotherapy | Breast Cancer Res | 2025 | 2 |
Clinical Studies 14
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Remotely Supervised Computerized Cognitive Stimulation to Reduce Post chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer NCT06027632 — exercise, organization and administration, breast neoplasms, neoplasms, executive function, cognitive dysfunction, drug therapy, breast, software, memory, chemotherapy | N/A | Recruiting | 2024 |
| Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer NCT05241405 — breast neoplasms, neoplasms, dietary supplements, double-blind method, food, capsules, fatigue, breast | N/A | Recruiting | 2022 |
| A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2 Breast Cancer NCT05132582 — injections, skin, breast neoplasms, genetics, pharmaceutical preparations, neoplasms, maintenance, breast, therapeutics, mouth, injections, subcutaneous, veins, trastuzumab, hyaluronoglucosaminidase | Phase 3 | Active not recruiting | 2022 |
| A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2 breast cancer 2023-503826-37-00 — breast neoplasms, neoplasms, maintenance, breast, response evaluation criteria in solid tumors, therapeutics, trastuzumab | Phase 3 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map